Brief: United Laboratories International Says Applications For Clinical Trial Of Class-1 New Drug Tul01101 Ointment Applied Approved By NMPA
26/10/2022 11:31
Oct 26 (Reuters) - United Laboratories International
Holdings Ltd 3933.HK :
* APPLICATIONS FOR CLINICAL TRIAL OF CLASS-1 NEW DRUG
TUL01101
OINTMENT APPLIED BY UNIT APPROVED BY NMPA
Further company coverage: 3933.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million